Meridian Bioscience Stock

Meridian Bioscience Rule of 40

The Rule of 40 of Meridian Bioscience (VIVO) as of Aug 6, 2026 is 27.46 %. In the previous year, Rule of 40 was 57.33 % — a change of -52.11% (lower).

Rule of 40

27.46 %

YoY

-52.11%

Last updated:

Rule of 40 of Meridian Bioscience is 2026 27.46 % . Rule of 40 of Meridian Bioscience was 2025 57.33 % . It decreases by -52.11% lower compared to the previous year.
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Rule of 40 of Meridian Bioscience is 27.46 % in 2026.

On Eulerpool you can find the complete historical development of Rule of 40 Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

Quality — Meridian Bioscience

All Key Metrics — Meridian Bioscience